SCHEMBL4753160

SCHEMBL4753160

Cc1cccc(CCCOC(=O)N2CCN(Cc3ccccc3)CC2)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.50
KDM4E B2RXH2 3/20 0.50
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
GRM5 P41594 1/20 0.48
HTR2A P28223 2/20 0.45
OPRM1 P35372 2/20 0.45
ADORA3 P0DMS8 1/20 0.45
HTR7 P34969 1/20 0.45
SIGMAR1 Q99720 1/20 0.45
SMN1; SMN2 Q16637 4/20 0.45
TSHR P16473 3/20 0.45
ALOX15 P16050 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
CHRM4 P08173 2/20 0.44
KMT2A Q03164 2/20 0.44
USP2 O75604 1/20 0.44
LMNA P02545 2/20 0.44
HTR1A P08908 1/20 0.44
DRD4 P21917 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4751002 0.95 ALDH1A1 (0.47) ALDH1A1KDM4ECYP1A2CYP3A4GRM5
SCHEMBL4751028 0.85 ALDH1A1 (0.45) ALDH1A1KDM4ETSHRKMT2AMAPK1
SCHEMBL4753349 0.81 ALDH1A1 (0.47) ALDH1A1KDM4EHTR7L3MBTL1KMT2A
SCHEMBL4753119 0.81 GRM5 (0.42) ALDH1A1KDM4ECYP1A2CYP3A4GRM5
SCHEMBL4750996 0.79 ALDH1A1 (0.45) ALDH1A1KDM4ECYP1A2SMN1; SMN2ALOX15
SCHEMBL317705 0.79 ADORA3 (0.57) ALDH1A1KDM4EHTR2AOPRM1ADORA3
SCHEMBL7475308 0.77 ALDH1A1 (0.70) ALDH1A1KDM4ESMN1; SMN2TSHRALOX15
SCHEMBL4753147 0.77 ALDH1A1 (0.45) ALDH1A1KDM4EHTR7L3MBTL1KMT2A
SCHEMBL4750772 0.77 ALDH1A1 (0.45) ALDH1A1KDM4EL3MBTL1KMT2AUSP2
SCHEMBL4751015 0.77 MAPT (0.43) ALDH1A1KDM4ECYP1A2GRM5SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008147864-A2 METHODS OF USING PIPERAZINE COMPOUNDS IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS XENON PHARMACEUTICALS INC. (CA) 2008-12-04 WO disclosed